Home > Result Summaries: Compounds > H5N1 Pandemic Influenza Vaccine > Result Summary for 107066

Result Summary for 107066

Result Summary

Protocol ID:	107066
Clinical Study ID:	107066
Official Title:	Controlled study of safety & immunogenicity of diff. antigen doses of a pandemic influenza vaccine candidate (GSK1562902A) given as 2 doses in children between 3 & 9 yrs of age
Phase:	phase 2
Study Indications or Diseases:	Influenza
Generic Name:	H5N1 Pandemic Influenza Vaccine
Trade/Product Name:	Pandemrix
Approved Drug Label:	http://www.gsk.com/products.html
Results Summary:	Click here to download result summary.
Citations:	Ballester A et al. Pediatric safety evaluation of an AS-adjuvanted H5N1 prepandemic candidate vaccine in children aged 6-9 years. A phase II study. Abstract presented at the 26th Annual Meeting of the European Society for Paediatric Infectious Diseases (ESPID), Graz, Austria, 13-17 May 2008. Ballester A et al. Pediatric safety evaluation of an AS-adjuvanted H5N1 prepandemic candidate vaccine in children aged 3-9 years. A phase II study. Abstract presented at the 13th International Congress on Infectious Diseases (ICID), Kuala Lumpur, Malaysia, 19-22 June 2008. Domingo JD et al. (2010) Immunogenicity and safety of H5N1 A/Vietnam/1194/2004 (Clade 1) AS03-adjuvanted prepandemic candidate influenza vaccines in children aged 3 to 9 years. a phase II, randomized, open, controlled study. Pediatr Infect Dis J. 29(6): e35–e46. Ballester A et al. Immunogenicity evaluation of an AS03-adjuvanted H5N1 prepandemic candidate vaccine in children aged 3-9 years. Abstract presented at the ICAAC-IDSA Joint Meeting, Washington DC, USA, 25-28 October 2008.